<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="320712">
  <stage>Registered</stage>
  <submitdate>15/10/2009</submitdate>
  <approvaldate>19/10/2009</approvaldate>
  <actrnumber>ACTRN12609000903280</actrnumber>
  <trial_identification>
    <studytitle>How does the anti-sickness drug dexamethasone influence the immune function in healthy volunteers?</studytitle>
    <scientifictitle>The influence of antiemetic doses of dexamethasone on lymphocyte sub-populations in healthy volunteers.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Immune function</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Normal development and function of the immune system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Single dose dexamethasone 2mg.4mg or 8 mg in 50 mls of normal saline infused over 15 minutes in healthy volunteers</interventions>
    <comparator>50 mls of normal saline infused over 15 minutes in healthy volunteers</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportions of lymphocyte subpopulations on blood analysis</outcome>
      <timepoint>Baseline, 4 hours, 24 hours and 168 hours after administration of drug</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Serum Macrophage Inhibitory Factor concentrations</outcome>
      <timepoint>Baseline, 4 hours, 24 hours and 168 hours after administration of drug</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy volunteers in American Society of Anaesthesiologists Classification (ASA) I-II</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1.Current drug therapy with antiemetics, steroids or serotonergic antidepressants 2.Active infection known or suspected metastatic disease 
3.Previous chemotherapy treatment 4.Allergy/intolerance to any of the study drugs (including renal or hepatic impairment, active peptic ulcer disease, ischaemic heart disease, QT prolongation, major psychiatric illness) 
5.Diabetes mellitus or history of seizures 6.Participation in any other research trial 7.Pregnant or possibility of</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation concealment via sealed opaque envelopes</concealment>
    <sequence>Computerised sequence generation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>8/06/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>32</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Clinical A/Professor Tomas Corcoran</primarysponsorname>
    <primarysponsoraddress>Department of Anaesthesia and Pain Medicine, Royal Perth Hospital, GPO Box X2213, Perth, W.A. 6847.</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Royal Perth Hospital</fundingname>
      <fundingaddress>Royal Perth Hospital, GPO Box X2213, Perth, W.A. 6847</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Lisa Hill</sponsorname>
      <sponsoraddress>c/o
Department of Anaesthesia and Pain Medicine, Royal Perth Hospital, GPO Box X2213, Perth, W.A. 6847.</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Dexamethasone is a drug commonly given to prevent postoperative nausea and vomiting. It also has properties that dampen the body's immune response to infection. In this study, we propose to examine healthy volunteers who were either given placebo or dexamethasone in 2mg, 4mg or 8 mg. Blood samples were taken before and after the intervention to determine the effect that they have on the immune system.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Perth Hospital</ethicname>
      <ethicaddress>Department of Anaesthesia and Pain Medicine, Royal Perth Hospital, GPO Box X2213, Perth, W.A. 6847.</ethicaddress>
      <ethicapprovaldate>7/06/2009</ethicapprovaldate>
      <hrec>EC 2008/194</hrec>
      <ethicsubmitdate>1/06/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical A/Professor Tomas Corcoran</name>
      <address>Department of Anaesthesia and Pain Medicine, Royal Perth Hospital, GPO Box X2213, Perth, W.A. 6847</address>
      <phone>+618 9224 1036</phone>
      <fax />
      <email>tomas.corcoran@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Clinical A/Professor Tomas Corcoran</name>
      <address>Department of Anaesthesia and Pain Medicine, Royal Perth Hospital, GPO Box X2213, Perth, W.A. 6847.</address>
      <phone>+618 9224 1036</phone>
      <fax />
      <email>tomas.corcoran@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Pui San Loh</name>
      <address>Department of Anaesthesia and Pain Medicine, Royal Perth Hospital, GPO Box X2213, Perth, W.A. 6847</address>
      <phone>+618 9224 1036</phone>
      <fax />
      <email>puisan.loh@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>